- Home
- ONFO vs VIVS Comparison
ONFO vs VIVS Comparison
Compare ONFO & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONFO
- VIVS
- Stock Information
- Founded
- ONFO 2018
- VIVS 2007
- Country
- ONFO United States
- VIVS United States
- Employees
- ONFO N/A
- VIVS N/A
- Industry
- ONFO Computer Software: Programming Data Processing
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ONFO Technology
- VIVS Health Care
- Exchange
- ONFO Nasdaq
- VIVS Nasdaq
- Market Cap
- ONFO 5.0M
- VIVS 4.7M
- IPO Year
- ONFO 2022
- VIVS N/A
- Fundamental
- Price
- ONFO $1.12
- VIVS $3.84
- Analyst Decision
- ONFO
- VIVS
- Analyst Count
- ONFO 0
- VIVS 0
- Target Price
- ONFO N/A
- VIVS N/A
- AVG Volume (30 Days)
- ONFO 1.7M
- VIVS 863.3K
- Earning Date
- ONFO 11-14-2025
- VIVS 11-07-2025
- Dividend Yield
- ONFO N/A
- VIVS N/A
- EPS Growth
- ONFO N/A
- VIVS N/A
- EPS
- ONFO N/A
- VIVS N/A
- Revenue
- ONFO $10,508,728.00
- VIVS $142,000.00
- Revenue This Year
- ONFO N/A
- VIVS $42.38
- Revenue Next Year
- ONFO N/A
- VIVS $15.42
- P/E Ratio
- ONFO N/A
- VIVS N/A
- Revenue Growth
- ONFO 78.36
- VIVS 94.52
- 52 Week Low
- ONFO $0.61
- VIVS $1.41
- 52 Week High
- ONFO $1.95
- VIVS $21.96
- Technical
- Relative Strength Index (RSI)
- ONFO 54.29
- VIVS 65.52
- Support Level
- ONFO $0.97
- VIVS $3.29
- Resistance Level
- ONFO $1.20
- VIVS $5.30
- Average True Range (ATR)
- ONFO 0.06
- VIVS 0.63
- MACD
- ONFO -0.04
- VIVS 0.17
- Stochastic Oscillator
- ONFO 93.33
- VIVS 58.39
About ONFO Onfolio Holdings Inc.
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place. The company operates in two business segments: Business to Business (B2B) and Business to Consumers (B2C). The majority of its revenue is generated from the Business-to-Business (B2B) segment, which includes the results of operations of Eastern Standard, RevenueZen, DDS Rank, SEO Butler, Contentellect, DealPipe, and Onfolio LLC.
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.